WINNIPEG, Manitoba, Oct. 16, 2026 – Kane Biotech Inc. (TSX-V:KNE), a biotechnology firm focused on combating microbial biofilms, announced today it has secured a $250,000 unsecured loan from Philip Renaud, the Chair of its Board of Directors and an approved control person. The loan is intended to provide additional working capital to support the company’s operations and strategic initiatives.
Loan Terms and Purpose
The financial arrangement, referred to as the “Loan,” is structured as an unsecured, non-interest-bearing facility that is repayable on demand. No bonuses or additional compensation were paid or are payable by Kane Biotech in connection with this loan. The company plans to utilize the funds for general working capital and corporate purposes. Repayment is anticipated to be sourced from future capital raises or general revenue streams.
Philip Renaud, in his capacity as Chair of the Board, stated, “This unsecured loan provides Kane Biotech with additional working capital as we continue to advance our corporate and commercial priorities. I remain committed to supporting the Company as management pursues its strategy and longer-term financing alternatives.”
Regulatory Compliance
The transaction has been identified as a “related party transaction” under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (MI 61-101) and TSX Venture Exchange Policy 5.9. Kane Biotech is availing itself of exemptions from the formal valuation and minority shareholder approval requirements stipulated in sections 5.5(a) and 5.7(1)(a) of MI 61-101. This exemption is applicable because the fair market value of the loan does not exceed 25% of the Company’s market capitalization.
About Kane Biotech Inc.
Kane Biotech is dedicated to the commercialization and development of innovative wound care treatments designed to disrupt biofilms and improve healing outcomes. Biofilms are recognized as a primary contributor to antibiotic resistance in wounds, leading to severe clinical consequences and substantial healthcare costs. The company’s flagship product line, revyve, targets both biofilms and wound bacteria.
The revyve product portfolio includes revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray, and revyve Antimicrobial Skin and Wound Cleanser. These products have received U.S. FDA 510(k) clearance. Furthermore, revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray have also obtained approval from Health Canada.
Further details about Kane Biotech’s technologies and products can be found on their website at revyvegel.com and revyvegel.ca.
Investor Information and Forward-Looking Statements
Investors seeking to stay informed about Kane Biotech’s developments are encouraged to sign up for the company’s email distribution list and follow its social media channels. The company’s website is kanebiotech.com, and its LinkedIn profile is available at https://www.linkedin.com/company/kanebiotech/. A presentation titled “Disrupting Biofilms to Save Limbs and Transform Wound Care” is also available.
For inquiries, Dr. Robert Huizinga, Interim CEO, can be reached at rhuizinga@kanebiotech.com or (780) 970-1100. Ray Dupuis, Chief Financial Officer, can be contacted at rdupuis@kanebiotech.com or (204) 298-2200.
This press release contains forward-looking statements regarding Kane Biotech Inc.’s expected use of the loan, its commercialization and development activities, its pursuit of financing alternatives, and the creation of long-term shareholder value. These statements are based on current management beliefs and available information. However, actual results may differ materially due to various risks and uncertainties, including the company’s financial condition, early stage of development, government regulation, market acceptance, technological change, intellectual property protection, and capital structure. A comprehensive overview of these risks and uncertainties can be found in the company’s filings with securities regulatory authorities, available at www.sedarplus.ca. Kane Biotech undertakes no obligation to update these forward-looking statements, except as required by law.
